Business
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
Brings nearly 20 years of investor relations and corporate communications experience to ProKidney WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) --
About this update from Prokidney Corp.
[{"type":"text","content":"Brings nearly 20 years of investor relations and corporate communications experience to ProKidney WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations. Dr. Schulman, who will report to Chief Financial Officer James Coulston, joins ProKidney after leading investor relations and corporate communication efforts at a number of early and late-stage Nasdaq-listed biopharmaceutical companies focused on the development of therapies to treat diseases of the immune system and kidneys. James Coulston, CFO of ProKidney, said: “On behalf of our team, I am excited to welcome Glenn to ProKidney. His scientific expertise, coupled with a deep experience gained from two decades in IR and corporate communications for emerging biotech companies, will be key to our long-term success as a publicly traded company. He has strong relationships throughout the investment community that will be highly beneficial as we work to increase awareness and exposure to our exciting story.” Prior to joining ProKidney, Dr. Schulman served as Vice President of Investor Relations at X4 Pharmaceuticals. Previous to that, Dr. Schulman was Senior Vice President, Investor Relations and Corporate Communications at Aurinia Pharmaceuticals; Executive Director, Investor Relations and Corporate Communications at Achillion Pharmaceuticals; and Director of Investor Relations and Medical Communications at CuraGen Corporation. In addition to his IR and corporate communications roles, he was a practicing pharmacist for 16 years. Dr. Schulman holds a bachelor’s degree in Pharmacy from Philadelphia College of Pharmacy; Doctor of Pharmacy degree from Rutgers University, Ernest Mario School of Pharmacy; and a Master’s in Public Health, Health Management from Yale University. He completed a post-doctoral fellowship in hospital administration at Memorial Sloan-Kettering Cancer Center. Dr. Schulman added, “Having recently entered the public markets following the business combination between ProKidney and SCS, ProKidney is at an important juncture where effective, proactive communication will be imperative to our capital markets succe...